January 31, 2023Open Access

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Key Points

Key points are not available for this paper at this time.

Abstract

These updated data demonstrate prolonged DFS benefit over placebo, reduced risk of local and distant recurrence, improved CNS DFS, and a consistent safety profile, supporting the efficacy of adjuvant osimertinib in resected EGFR-mutated NSCLC.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Herbst et al. (Tue,) studied this question.

synapsesocial.com/papers/69d1ba585cbcefc93738f775 https://doi.org/https://doi.org/10.1200/jco.22.02186

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC2021 · 151 citations
2Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer2020 · 1,759 citations
3VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study2022 · 72 citations
4The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer2016 · 297 citations
5AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer2014 · 2,228 citations

Demander à l'IA

Bookmark

View Full Paper